Home
Ultralife Corporation
Ultralife Corporation Reports Third Quarter Results
Business
Nov 18 2025
11 min read

Ultralife Corporation Reports Third Quarter Results

news images

NEWARK, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2025 with the following results:

  • Sales of $43.4 million increased 21.5% from $35.7 million for the third quarter of 2024; excluding Electrochem, sales of $36.6 million increased 2.5%

  • Gross profit of $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the third quarter of 2024

  • Operating loss of $1.0 million, reflecting one-time non-recurring costs of $1.1 million, including a $.5 million provision to close our Calgary facility, compared to operating income of $0.5 million for the third quarter of 2024

  • GAAP EPS of ($0.07) compared to $0.02 for the third quarter of 2024

  • Adjusted EBITDA of $2.0 million compared to $1.9 million for the third quarter of 2024

  • Backlog of $90.1 million exiting the third quarter of 2025 compared to $84.5 million exiting the second quarter of 2025

During the third quarter of 2025, Ultralife made the decision to close its battery pack assembly facility located in Calgary, Canada. Accordingly the Company recorded a $.5 million charge to cover employee severance and termination costs, the remaining lease costs which run through July 31, 2026 and the estimated costs to close the facility and relocate the equipment and inventory to the Company’s facility in Houston, Texas. Management expects to complete the closure in the first quarter of 2026 and to realize estimated annual savings of approximately $.8 million thereafter primarily resulting from the reduction of labor and the elimination of the leased facility.

“Although revenue grew 2.5% organically and 21.5% including the Electrochem acquisition for the third quarter, supply chain issues caused manufacturing inefficiencies in our Battery & Energy Products business and orders continued to be delayed in our Communications Systems business, both of which impacted overall profitability. In response, we are intensifying our lean and process improvement initiatives, improving supply chain resiliency and rationalizing our manufacturing operations,” said Mike Manna, President and Chief Executive Officer.

“These actions are critical to ensuring we are best prepared to optimize the operating leverage of our business model as we advance several new products into qualification and production, and capitalize on an expanding pipeline of opportunities consisting primarily of large, multi-year programs,” added Manna. “Our priorities remain converting long-term new product development efforts into revenue, advancing vertical integration in the oil & gas segment, and maintaining a strong focus on operational efficiency initiatives to deliver sustainable profitable growth and maximizing the value of our global brand.”

Third Quarter 2025 Financial Results

Revenue was $43.4 million, an increase of $7.7 million, or 21.5%, as compared to revenue of $35.7 million for the third quarter of 2024. Battery & Energy Products sales increased 22.8% to $39.9 million compared to $32.5 million last year reflecting the inclusion of Electrochem Solutions, Inc. (“Electrochem”). Excluding Electrochem, Battery & Energy Products sales increased 1.9% with government/defense sales increasing 19.0%, reflecting strong demand from a U.S.-based global prime, partially offset by a 5.7% decrease in commercial sales, primarily reflecting declines in oil & gas and medical sales. Communications Systems sales increased 8.2% to $3.4 million compared to $3.2 million for the same period last year.

Gross profit was $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the same quarter a year ago. Battery & Energy Products gross margin was 22.1%, compared to 24.7% last year, primarily due to manufacturing inefficiencies resulting from quality issues associated with some incoming raw materials lowering factory throughput at some of our locations and less favorable sales mix. Communications Systems gross margin was 23.3% compared to 20.0% last year, primarily due to product mix.

Operating expenses were $10.6 million, compared to $8.2 million for the third quarter of 2024, reflecting the inclusion of Electrochem and one-time non-recurring costs of $1.1 million related to the closing of our Calgary facility, costs related to our acquisition of Electrochem and transition to Ultralife systems, and litigation expenses incurred for our cyber insurance claim. Operating expenses were 24.4% of revenue compared to 22.9% of revenue for the year-earlier period. Excluding the one-time costs, operating expenses were 21.9% of revenues for the third quarter of 2025.

Operating loss was $1.0 million compared to operating income of $.5 million last year, primarily resulting from the one-time non-recurring expenses incurred and lower gross margin for our Battery & Energy Products segment in 2025.

Other expense, reported below operating income was $.8 million, comprised of interest expense from the financing of our Electrochem acquisition on October 31, 2024 and foreign currency gains from the strengthening of the U.S. dollar, compared to $.2 million for the same period last year.

Net (loss) income attributable to Ultralife Corporation was ($1.2) million or ($0.07) per basic and diluted share on a GAAP basis, compared to $.3 million or $0.02 per diluted share for the third quarter of 2024.

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was $2.0 million for the third quarter of 2025, or 4.7% of sales, compared to $1.9 million, or 5.4% of sales, for the year-earlier period. On a trailing twelve-month basis, adjusted EBITDA was $15.5 million or 8.3% of sales.

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

Conference Call Information

Ultralife will hold its third quarter earnings conference call today at 8:30 ET.

To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: https://register-conf.media-server.com/register/BI0301fd92021249ef830e0c9c7be9f917. This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions including the impact of tariffs and inflation, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of our new products on a global basis, and disruptions, delays or material price increases in our supply of raw materials and components due to business conditions, new or additional tariffs, global conflicts, weather or other factors not under our control. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.


 

 

 

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
(Dollars in Thousands)

(Unaudited)

 

ASSETS

 

 

 

 

 

 

September 30,
2025

 

December 31,
2024

 

Current Assets:

 

 

 

 

Cash

$9,260

 

$6,854

 

Trade Accounts Receivable, Net

30,929

 

29,370

 

Inventories, Net

52,747

 

51,363

 

Prepaid Expenses and Other Current Assets

7,683

 

9,573

 

Total Current Assets

100,619

 

97,160

 

 

 

 

 

 

Property, Plant and Equipment, Net

40,536

 

40,485

 

Goodwill

45,336

 

45,006

 

Other Intangible Assets, Net

23,407

 

24,557

 

Deferred Income Taxes, Net

8,212

 

8,413

 

Other Non-Current Assets

4,136

 

4,830

 


Total Assets

$222,246

 

$220,451

 

 


LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities:

Accounts Payable

$14,164

 

$14,160

 

Current Portion of Long-Term Debt

3,781

 

2,750

 

Accrued Compensation and Related Benefits

2,935

 

2,911

 

Accrued Expenses and Other Current Liabilities

12,818

 

9,470

 

Total Current Liabilities

33,698

 

29,291

 

Long-Term Debt, Net

46,518

 

51,502

 

Deferred Income Taxes

1,358

 

1,443

 

Other Non-Current Liabilities

3,239

 

4,028

 

Total Liabilities

84,813

 

86,264

 

 

 

 

 

 

Shareholders' Equity:

 

 

 

 

Common Stock

2,109

 

2,107

 

Capital in Excess of Par Value

192,622

 

191,828

 

Accumulated Deficit

(32,918)

 

(34,442)

 

Accumulated Other Comprehensive Loss

(3,058)

 

(4,006)

 

Treasury Stock

(21,492)

 

(21,492)

 

Total Ultralife Equity

137,263

 

133,995

 

Non-Controlling Interest

170

 

192

 

Total Shareholders’ Equity

137,433

 

134,187

 

 

 

 

 

 

Total Liabilities and Shareholders' Equity

$222,246

 

$220,451

 


 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In Thousands Except Per Share Amounts)

(Unaudited)

 

 

 

 

 

 

 

 

 

Three-Month Period Ended

 

Nine-Month Period Ended

 

September 30,

 

September 30,

 

September 30,

 

September 30,

 

2025

 

2024

 

2025

 

2024

Revenues:

 

 

 

 

 

 

 

Battery & Energy Products

$39,946

 

$32,529

 

$132,134

 

$104,201

Communications Systems

3,425

 

3,165

 

10,544

 

16,403

Total Revenues

43,371

 

35,694

 

142,678

 

120,604

 

 

 

 

 

 

 

 

Cost of Products Sold:

 

 

 

 

 

 

 

Battery & Energy Products

31,126

 

24,482

 

101,039

 

77,215

Communications Systems

2,626

 

2,530

 

7,674

 

11,674

Total Cost of Products Sold

33,752

 

27,012

 

108,713

 

88,889

 

 

 

 

 

 

 

 

Gross Profit

9,619

 

8,682

 

33,965

 

31,715

 

 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

 

 

Research and Development

2,855

 

2,101

 

7,577

 

5,854

Selling, General and Administrative

7,715

 

6,070

 

21,684

 

17,370

Total Operating Expenses

10,570

 

8,171

 

29,261

 

23,224

 

 

 

 

 

 

 

 

Operating (Loss) Income

(951)

 

511

 

4,704

 

8,491

 

 

 

 

 

 

 

 

Other Expense

800

 

158

 

2,896

 

685

(Loss) Income Before Income Taxes

(1,751)

 

353

 

1,808

 

7,806

 

 

 

 

 

 

 

 

Income Tax (Benefit) Provision

(504)

 

74

 

306

 

1,630

 

 

 

 

 

 

 

 

Net (Loss) Income

(1,247)

 

279

 

1,502

 

6,176

 

 

 

 

 

 

 

 

Net (Loss) Income Attributable to Non-Controlling Interest

(27)

 

21

 

(22)

 

58

 

 

 

 

 

 

 

 

Net (Loss) Income Attributable to Ultralife Corporation

($1,220)

 

$258

 

$1,524

 

$6,118

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (Loss) Income Per Share Attributable to Ultralife Common Shareholders – Basic

($.07)

 

$.02

 

$.09

 

$.37

 

 

 

 

 

 

 

 

Net (Loss) Income Per Share Attributable to Ultralife Common Shareholders – Diluted

($.07)

 

$.02

 

$.09

 

$.37

 

 

 

 

 

 

 

 

Weighted Average Shares Outstanding – Basic

16,646

 

16,625

 

16,638

 

16,530

 

 

 

 

 

 

 

 

Weighted Average Shares Outstanding – Diluted

16,646

 

16,874

 

16,699

 

16,742


Non-GAAP Financial Measures

Adjusted EBITDA

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to GAAP financial measures. We define adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.



ULTRALIFE CORPORATION AND SUBSIDIARIES
CALCULATION OF ADJUSTED EBITDA
(Dollars in Thousands)
(Unaudited)

 

 

 

 

 

Three-Month Period Ended

 

Nine-Month Period Ended

 

September 30,
2025

 

September 30,
2024

 

September 30,
2025

 

September 30,
2024

 

 

 

 

 

 

 

 

Net (Loss) Income Attributable to Ultralife Corporation

($1,220)

 

$258

 

$1,524

 

$6,118

Adjustments:

 

 

 

 

 

 

 

Interest Expense, Net

992

 

173

 

3,016

 

1,111

Income Tax (Benefit) Provision

(504)

 

74

 

306

 

1,630

Depreciation Expense

1,008

 

765

 

2,966

 

2,294

Amortization Expense

411

 

229

 

1,226

 

684

Stock-Based Compensation Expense

236

 

170

 

698

 

490

Severance and Other Costs for Plant Closure

491

 

-

 

641

 

-

Acquisition and Other Non-Recurring Costs

594

 

250

 

1,112

 

-

Non-Cash Purchase Accounting Adjustment

40

 

-

 

120

 

250

Adjusted EBITDA

$2,048

 

$1,919

 

$11,609

 

$12,577


Company Contact:
Ultralife Corporation
Philip A. Fain
(315) 210-6110
pfain@ulbi.com

 

Investor Relations Contact:
Alliance Advisors IR
Jody Burfening/Alex Villalta
(212) 838-3777
avillalta@allianceadvisors.com